Matteo Bramuzzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matteo Bramuzzo has a total of 543 co-authors. Here are the top co-authors by number of shared publications:
Serena Arrigo
Gastroenterology Unit, IRCCS Istituto Giannina Gaslini Genova Italy
15 shared publications- Lorenzo Norsa
Department of Paediatrics, Vittore Buzzi Children's Hospital, University of Milan, Milan, Italy
13 shared publications Claudio Romano
12 shared publicationsGiovanna Zuin
Pediatric Department Fondazione IRCCS San Gerardo dei Tintori Monza Italy
12 shared publications- Luca Scarallo
Gastroenterology and Nutrition Unit Meyer Children's Hospital IRCCS Florence Italy
11 shared publications Enrico Felici
Pediatric and Pediatric Emergency Unit, “Umberto Bosio” Center for Digestive Diseases, The Children Hospital, AO SS Antonio e Biagio e C. Arrigo Alessandria Italy
10 shared publications
Latest Publications
- 12 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Pediatric inflammatory bowel diseases in patients with genetic syndromes: A case–control multicentre SIGENP study
Objectives: To characterize the clinical phenotype and long‐term outcomes of pediatric inflammatory bowel disease (IBD) in patients with genetic syndromes. Methods: Multicenter observational case‐control study using data from the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition IBD registry. Patients diagnosed with pediatric‐onset IBD (p = 0.004) and height (−1.43 z ‐score, p < 0.001); these differences persisted at follow‐up. Diagnostic delay was longer in syndromic patients (+6.5 months, p = 0.045). Abdominal pain was less frequent at presentation ( p = 0.01). Syndromic patients had more hospitalizations (IBD‐related incidence rate ratio [IRR] 1.23, p = 0.033; non‐IBD IRR 1.65, p < 0.001), more comorbidities (odds ratio [OR] 18.2, p < 0.001), and greater use of non‐IBD medications (OR 8.17, p = 0.004). The risk of additional autoimmune diseases was higher but not statistically significant. Conclusions: Pediatric IBD patients with genetic syndromes show impaired growth and delayed diagnosis, while intestinal disease activity and treatment exposure are comparable to non‐syndromic peers. The higher burden of comorbidities and hospitalizations indicates greater healthcare complexity and diagnostic challenges; early recognition and coordinated multidisciplinary care are reasonable clinical considerations, but their impact on outcomes requires prospective evaluation.
- 12 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Pediatric inflammatory bowel diseases in patients with genetic syndromes: A case–control multicentre SIGENP study
Objectives: To characterize the clinical phenotype and long‐term outcomes of pediatric inflammatory bowel disease (IBD) in patients with genetic syndromes. Methods: Multicenter observational case‐control study using data from the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition IBD registry. Patients diagnosed with pediatric‐onset IBD (p = 0.004) and height (−1.43 z ‐score, p < 0.001); these differences persisted at follow‐up. Diagnostic delay was longer in syndromic patients (+6.5 months, p = 0.045). Abdominal pain was less frequent at presentation ( p = 0.01). Syndromic patients had more hospitalizations (IBD‐related incidence rate ratio [IRR] 1.23, p = 0.033; non‐IBD IRR 1.65, p < 0.001), more comorbidities (odds ratio [OR] 18.2, p < 0.001), and greater use of non‐IBD medications (OR 8.17, p = 0.004). The risk of additional autoimmune diseases was higher but not statistically significant. Conclusions: Pediatric IBD patients with genetic syndromes show impaired growth and delayed diagnosis, while intestinal disease activity and treatment exposure are comparable to non‐syndromic peers. The higher burden of comorbidities and hospitalizations indicates greater healthcare complexity and diagnostic challenges; early recognition and coordinated multidisciplinary care are reasonable clinical considerations, but their impact on outcomes requires prospective evaluation.
- 17 September 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Current practices and unmet needs in the management of Clostridioides difficile infection in pediatric inflammatory bowel disease: A national survey
Objectives: Children with inflammatory bowel disease (IBD) are at increased risk for Clostridioides difficile infection (CDI), which is associated with worse clinical outcomes. We aimed to assess current diagnostic and therapeutic practices for CDI among Italian pediatric IBD centers. Methods: A nationwide survey was conducted in 2025 using a structured 28‐item questionnaire distributed to all pediatric IBD centers in Italy. Items addressed diagnostic strategies, treatment approaches, recurrence management, and immunosuppressive therapy handling in children with IBD and CDI. Results: Twenty‐seven centers responded (response rate, 90%). Diagnostic approaches varied: toxin enzyme immunoassays (EIA) were indicated by 21/27 centers (78%), glutamate dehydrogenase (GDH) testing by 19/27 (70%), and nucleic acid amplification tests (NAAT) by 13/27 (48%). Routine CDI testing at IBD diagnosis was indicated by 12/27 centers (44%), whereas 23/27 (85%) reported testing during IBD flares. For a first non‐severe episode, vancomycin and metronidazole were equally identified as preferred first‐line options (18/27; 66% each). Oral vancomycin was the preferred treatment for recurrent CDI (26/27; 96%). Third or subsequent recurrences prompted consideration of fidaxomicin (19/27; 70%), fecal microbiota transplantation (6/27; 22%), and bezlotoxumab (2/27; 7%). In fulminant CDI, 7/27 centers (26%) indicated adding fidaxomicin to standard therapy. In acute severe colitis with concomitant CDI at diagnosis, 18/27 centers (67%) described a cautious approach to biologic initiation. Conclusions: This nationwide survey highlights substantial unmet needs in CDI management in pediatric IBD, including variability in diagnostic strategies, lack of consensus on first‐line therapy, and uncertainty regarding immunosuppressive management, supporting the need for evidence‐based pediatric‐specific guidelines.
- 17 September 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Current practices and unmet needs in the management of Clostridioides difficile infection in pediatric inflammatory bowel disease: A national survey
Objectives: Children with inflammatory bowel disease (IBD) are at increased risk for Clostridioides difficile infection (CDI), which is associated with worse clinical outcomes. We aimed to assess current diagnostic and therapeutic practices for CDI among Italian pediatric IBD centers. Methods: A nationwide survey was conducted in 2025 using a structured 28‐item questionnaire distributed to all pediatric IBD centers in Italy. Items addressed diagnostic strategies, treatment approaches, recurrence management, and immunosuppressive therapy handling in children with IBD and CDI. Results: Twenty‐seven centers responded (response rate, 90%). Diagnostic approaches varied: toxin enzyme immunoassays (EIA) were indicated by 21/27 centers (78%), glutamate dehydrogenase (GDH) testing by 19/27 (70%), and nucleic acid amplification tests (NAAT) by 13/27 (48%). Routine CDI testing at IBD diagnosis was indicated by 12/27 centers (44%), whereas 23/27 (85%) reported testing during IBD flares. For a first non‐severe episode, vancomycin and metronidazole were equally identified as preferred first‐line options (18/27; 66% each). Oral vancomycin was the preferred treatment for recurrent CDI (26/27; 96%). Third or subsequent recurrences prompted consideration of fidaxomicin (19/27; 70%), fecal microbiota transplantation (6/27; 22%), and bezlotoxumab (2/27; 7%). In fulminant CDI, 7/27 centers (26%) indicated adding fidaxomicin to standard therapy. In acute severe colitis with concomitant CDI at diagnosis, 18/27 centers (67%) described a cautious approach to biologic initiation. Conclusions: This nationwide survey highlights substantial unmet needs in CDI management in pediatric IBD, including variability in diagnostic strategies, lack of consensus on first‐line therapy, and uncertainty regarding immunosuppressive management, supporting the need for evidence‐based pediatric‐specific guidelines.
- Open Access
- 12 September 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (12) , 1523-1531
The PREFERENDO Delphi consensus: Advanced reporting standards for pediatric gastrointestinal endoscopy
- 12 September 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (12) , 1523-1531
Open AccessThe PREFERENDO Delphi consensus: Advanced reporting standards for pediatric gastrointestinal endoscopy
- Open Access
- 12 September 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (11) , 1389-1396
The PREFERENDO Delphi consensus: Minimum quality standards and core reporting elements for pediatric gastrointestinal endoscopy
- 12 September 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (11) , 1389-1396
Open AccessThe PREFERENDO Delphi consensus: Minimum quality standards and core reporting elements for pediatric gastrointestinal endoscopy
- 3 September 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (9)
Upadacitinib treatment in pediatric Crohn’s disease: 52-week outcomes of an international multicenter retrospective cohort study from the pediatric IBD Porto Group of ESPGHAN
Background and aims: Data on upadacitinib maintenance therapy in pediatric Crohn’s disease (CD) are scarce. We aimed to evaluate the effectiveness, safety, and dosing of upadacitinib as maintenance therapy in pediatric CD. Methods: Children treated with upadacitinib for maintenance of remission of active CD from 35 centers affiliated with the Porto Group of ESPGHAN were included in this retrospective cohort study. Data on demographic, clinical, laboratory, endoscopic, and imaging findings and on adverse events (AEs) were recorded over 52 weeks of follow-up. Results: A total of 120 children were included (91 receiving upadacitinib as monotherapy and 29 as combination advanced therapy, mean age 15.4 ± 2.5 years). Prior to upadacitinib induction, 119/120 (99%) children had been treated with biologic therapies, 104 (87%) with two or more biologics and 98 (82%) had failed both vedolizumab and ustekinumab. Clinical remission and corticosteroid-free clinical remission (CFR) were observed after upadacitinib induction in 77 (64%) and 72 (60%) children, respectively. By week 52, 74 (62%) children achieved both clinical remission and CFR, and CFR was sustained in 66 (55%) children. CFR with normal C-reactive protein levels was achieved in 50% of children and CFR with fecal calprotectin levels <150 µg/g was achieved in 33% of children by week 52. Fifty-three (44%) children sustained AEs, two of which were serious (severe acne and intestinal perforation). The most frequent AEs were acne (n = 23), hyperlipidemia (n = 18), and infections (n = 14). Conclusion: Upadacitinib is an effective maintenance therapy for refractory pediatric CD. Effectiveness should be weighed against the potential risks of AEs.
- 3 September 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (9)
Upadacitinib treatment in pediatric Crohn’s disease: 52-week outcomes of an international multicenter retrospective cohort study from the pediatric IBD Porto Group of ESPGHAN
Background and aims: Data on upadacitinib maintenance therapy in pediatric Crohn’s disease (CD) are scarce. We aimed to evaluate the effectiveness, safety, and dosing of upadacitinib as maintenance therapy in pediatric CD. Methods: Children treated with upadacitinib for maintenance of remission of active CD from 35 centers affiliated with the Porto Group of ESPGHAN were included in this retrospective cohort study. Data on demographic, clinical, laboratory, endoscopic, and imaging findings and on adverse events (AEs) were recorded over 52 weeks of follow-up. Results: A total of 120 children were included (91 receiving upadacitinib as monotherapy and 29 as combination advanced therapy, mean age 15.4 ± 2.5 years). Prior to upadacitinib induction, 119/120 (99%) children had been treated with biologic therapies, 104 (87%) with two or more biologics and 98 (82%) had failed both vedolizumab and ustekinumab. Clinical remission and corticosteroid-free clinical remission (CFR) were observed after upadacitinib induction in 77 (64%) and 72 (60%) children, respectively. By week 52, 74 (62%) children achieved both clinical remission and CFR, and CFR was sustained in 66 (55%) children. CFR with normal C-reactive protein levels was achieved in 50% of children and CFR with fecal calprotectin levels <150 µg/g was achieved in 33% of children by week 52. Fifty-three (44%) children sustained AEs, two of which were serious (severe acne and intestinal perforation). The most frequent AEs were acne (n = 23), hyperlipidemia (n = 18), and infections (n = 14). Conclusion: Upadacitinib is an effective maintenance therapy for refractory pediatric CD. Effectiveness should be weighed against the potential risks of AEs.
- 1 August 2026
- Published by Wiley in Acta Paediatrica
- Vol. 115 (11) , 2389-2397
Gastrointestinal Adverse Events Following Rotavirus Vaccination in Children: A Systematic Review
Aim: To review current evidence regarding the occurrence, clinical presentation, and management of gastrointestinal adverse events following administration of RV1 and RV5 rotavirus vaccines in the paediatric population. Methods: A systematic literature search was performed between April and August 2025. The review included randomised controlled trials, meta‐analyses, and relevant case reports published from 2007 onwards. Primary outcomes focused on gastrointestinal manifestations: Prolongeddiarrhoea, intussusception, and immune‐mediated diseases. Secondary outcomes included clinical management of GI post‐vaccination events. Results: Out of 197 identified studies, 86 met the inclusion criteria. Mild gastrointestinal symptoms, such as transient diarrhoea and vomiting, were common but typically self‐limited. No increased risk of prolonged diarrhoea was identified in healthy infants, although rare cases were reported in children with severe immunodeficiencies. Data showed no increased risk of intussusception or immune‐mediated conditions like celiac disease or inflammatory bowel disease. Specific high‐risk groups, including infants with a history of intussusception, severe combined immunodeficiency, or metabolic disorders, were associated with a higher incidence of adverse events. Conclusion: RV1 and RV5 vaccines maintain an excellent safety profile. In high‐income settings, prolonged post‐vaccination diarrhoea should be considered a clinical marker for underlying immunodeficiency rather than a risk factor for future immune‐mediated intestinal disorders.
- 1 August 2026
- Published by Wiley in Acta Paediatrica
- Vol. 115 (11) , 2389-2397
Gastrointestinal Adverse Events Following Rotavirus Vaccination in Children: A Systematic Review
Aim: To review current evidence regarding the occurrence, clinical presentation, and management of gastrointestinal adverse events following administration of RV1 and RV5 rotavirus vaccines in the paediatric population. Methods: A systematic literature search was performed between April and August 2025. The review included randomised controlled trials, meta‐analyses, and relevant case reports published from 2007 onwards. Primary outcomes focused on gastrointestinal manifestations: Prolongeddiarrhoea, intussusception, and immune‐mediated diseases. Secondary outcomes included clinical management of GI post‐vaccination events. Results: Out of 197 identified studies, 86 met the inclusion criteria. Mild gastrointestinal symptoms, such as transient diarrhoea and vomiting, were common but typically self‐limited. No increased risk of prolonged diarrhoea was identified in healthy infants, although rare cases were reported in children with severe immunodeficiencies. Data showed no increased risk of intussusception or immune‐mediated conditions like celiac disease or inflammatory bowel disease. Specific high‐risk groups, including infants with a history of intussusception, severe combined immunodeficiency, or metabolic disorders, were associated with a higher incidence of adverse events. Conclusion: RV1 and RV5 vaccines maintain an excellent safety profile. In high‐income settings, prolonged post‐vaccination diarrhoea should be considered a clinical marker for underlying immunodeficiency rather than a risk factor for future immune‐mediated intestinal disorders.
- 22 July 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Disorders of Gut-Brain Interaction-Like Symptoms in Children With Inflammatory Bowel Disease: A Multicenter Prospective Study From the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition
INTRODUCTION: Disorders of gut-brain interaction (DGBI) are frequently reported in patients with inflammatory bowel disease (IBD), but pediatric data are scarce. We aimed to determine the prevalence of DGBI-like symptoms in children with quiescent IBD compared with healthy controls (HC), and to evaluate their impact on health-related quality of life, anxiety and symptoms burden. METHODS: This multicenter, prospective, observational study enrolled children aged 10–18 years with biochemically quiescent IBD, with or without endoscopic confirmation of remission from 7 European Society of Pediatric Gastroenterology, Hepatology and Nutrition centers (January 2021–August 2023). Age and sex-matched HC were recruited through primary care pediatricians and screened for subclinical inflammation using fecal calprotectin. DGBI were assessed using Rome IV criteria. Health-related quality of life and psychological burden were evaluated using IMPACT III, PROMIS Anxiety, Visceral Sensitivity Index–Child, and Behavioral Response Questionnaire–Child. RESULTS: A total of 253 children were enrolled (IBD: n = 131; HC: n = 122). The prevalence of DGBI-like symptoms did not differ between IBD and HC (34.4% vs 41.8%, P = 0.30). Functional abdominal pain disorders were present in 24.4% of children with IBD. Children with IBD and DGBI-like symptoms showed significantly lower IMPACT III scores compared with those without DGBI [median 74 (interquartile range 62.5–81) vs 84 (70–90); P = 0.001], with the greatest impairment in IBD symptoms, energy, and social domains. PROMIS Anxiety scores were higher in the DGBI group [31 (20–44) vs 21.5 (16–28); P < 0.001], with a greater proportion exceeding the clinical threshold (>50) (17.8% vs 3.5%; P = 0.008). Female sex was the only independent predictor of DGBI (OR 5.2, 95% CI 1.6–16.1; P = 0.005). DISCUSSION: DGBI-like symptoms are common in children with quiescent IBD and are associated with a substantial psychological and quality-of-life burden.
- 22 July 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Disorders of Gut-Brain Interaction-Like Symptoms in Children With Inflammatory Bowel Disease: A Multicenter Prospective Study From the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition
INTRODUCTION: Disorders of gut-brain interaction (DGBI) are frequently reported in patients with inflammatory bowel disease (IBD), but pediatric data are scarce. We aimed to determine the prevalence of DGBI-like symptoms in children with quiescent IBD compared with healthy controls (HC), and to evaluate their impact on health-related quality of life, anxiety and symptoms burden. METHODS: This multicenter, prospective, observational study enrolled children aged 10–18 years with biochemically quiescent IBD, with or without endoscopic confirmation of remission from 7 European Society of Pediatric Gastroenterology, Hepatology and Nutrition centers (January 2021–August 2023). Age and sex-matched HC were recruited through primary care pediatricians and screened for subclinical inflammation using fecal calprotectin. DGBI were assessed using Rome IV criteria. Health-related quality of life and psychological burden were evaluated using IMPACT III, PROMIS Anxiety, Visceral Sensitivity Index–Child, and Behavioral Response Questionnaire–Child. RESULTS: A total of 253 children were enrolled (IBD: n = 131; HC: n = 122). The prevalence of DGBI-like symptoms did not differ between IBD and HC (34.4% vs 41.8%, P = 0.30). Functional abdominal pain disorders were present in 24.4% of children with IBD. Children with IBD and DGBI-like symptoms showed significantly lower IMPACT III scores compared with those without DGBI [median 74 (interquartile range 62.5–81) vs 84 (70–90); P = 0.001], with the greatest impairment in IBD symptoms, energy, and social domains. PROMIS Anxiety scores were higher in the DGBI group [31 (20–44) vs 21.5 (16–28); P < 0.001], with a greater proportion exceeding the clinical threshold (>50) (17.8% vs 3.5%; P = 0.008). Female sex was the only independent predictor of DGBI (OR 5.2, 95% CI 1.6–16.1; P = 0.005). DISCUSSION: DGBI-like symptoms are common in children with quiescent IBD and are associated with a substantial psychological and quality-of-life burden.
- Open Access
- 21 February 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (5) , 670-674
ERCP-based management of pediatric chronic pancreatitis: Results from a retrospective long-term multicentric study
- 21 February 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (5) , 670-674
Open AccessERCP-based management of pediatric chronic pancreatitis: Results from a retrospective long-term multicentric study
- Open Access
- 13 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 14 (CP)
Improving Endoscopic Scoring Accuracy in Pediatric Inflammatory Bowel Disease: Impact of a Focused Training Intervention
Background High variability has been reported in assessing endoscopic scoring systems for pediatric inflammatory bowel disease (IBD). This study assessed whether a structured training could improve interobserver agreement when scoring IBD endoscopy findings. Methods Ten ileocolonoscopic videos were scored using the Mayo Endoscopic Score (MES) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) for ulcerative colitis, and the Simple Endoscopic Score for Crohn’s Disease (SES-CD). Ten expert endoscopists and ten trainees evaluated the videos before and after a focused training session. Agreement was measured using intraclass correlation coefficient (ICC) and Fleiss kappa (κ), and perceived benefit was surveyed. Results For MES, κ slightly improved among experts, but ICC declined; trainees showed stable κ and improved ICC. The UCEIS agreement was stable in experts and slightly improved in trainees. The SES-CD scores showed improved agreement for both groups, with trainee accuracy improving from 74% to 86% (Δ = 12%, p = 0.051). Both groups reported subjective improvement, although not statistically significant. Conclusions Interobserver agreement ranged from moderate to good. Structured training produced only modest improvements, especially in SES-CD scoring, with limited overall effect on scoring consistency.
- 13 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 14 (CP)
Open AccessImproving Endoscopic Scoring Accuracy in Pediatric Inflammatory Bowel Disease: Impact of a Focused Training Intervention
Background High variability has been reported in assessing endoscopic scoring systems for pediatric inflammatory bowel disease (IBD). This study assessed whether a structured training could improve interobserver agreement when scoring IBD endoscopy findings. Methods Ten ileocolonoscopic videos were scored using the Mayo Endoscopic Score (MES) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) for ulcerative colitis, and the Simple Endoscopic Score for Crohn’s Disease (SES-CD). Ten expert endoscopists and ten trainees evaluated the videos before and after a focused training session. Agreement was measured using intraclass correlation coefficient (ICC) and Fleiss kappa (κ), and perceived benefit was surveyed. Results For MES, κ slightly improved among experts, but ICC declined; trainees showed stable κ and improved ICC. The UCEIS agreement was stable in experts and slightly improved in trainees. The SES-CD scores showed improved agreement for both groups, with trainee accuracy improving from 74% to 86% (Δ = 12%, p = 0.051). Both groups reported subjective improvement, although not statistically significant. Conclusions Interobserver agreement ranged from moderate to good. Structured training produced only modest improvements, especially in SES-CD scoring, with limited overall effect on scoring consistency.
- 19 September 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (9)
Real-life durability and risk factors for biologic discontinuation in pediatric inflammatory bowel disease: results from the SIGENP IBD registry
Background and aims: This study aims to evaluate the real-life durability of biologic therapies and to identify factors associated with biologic persistence in pediatric inflammatory bowel disease (IBD). Methods: We analyzed data from the IBD-registry of the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (SIGENP) of patients initiating biologics between 2009 and 2022 and ≥1-year follow-up. Results: A total of 1184 patients (747 with Crohn’s disease [CD], 437 with ulcerative colitis or IBD unclassified [UC/IBD-U]) were included, accounting for 1709 treatment courses. The median follow-up was 43 months (interquartile range 28-64). Overall, 33% received a second-line biologic, 9% third-line, and 2% fourth-line. First-line biologic durability was significantly lower in UC/IBD-U vs CD, with inferior persistence at 1, 2, and 3 years (61%, 51%, and 44% vs 88%, 75%, and 67%; hazard ratios [HR]: 1.5, 95% confidence interval [CI] 1.2-1.9, P = .002). In CD, infliximab had inferior durability then adalimumab (72%, 59%, and 50% vs 91%, 82%, and 77%; HR 2.0, 95% CI, 1.5-2.7, P < .0001). In both CD and UC/IBD-U, age <6 years was a risk factor for treatment discontinuation (HR 1.8, 95% CI, 1.2-2.7, P < .01) while therapeutic drug monitoring (TDM) emerged as protective (HR 0.5, 95% CI, 0.4-0.7, P < .0001). Combination with an immunomodulator had no significant impact on durability (HR 0.9, 95% CI, 0.8-1.2, P = .54). Conclusions: Biologic persistence varied by disease type and biologic agent. TDM was associated with longer treatment durability, while combination therapy had a limited effect. Further prospective studies are needed to refine biologics optimization strategies in pediatric IBD.
- 19 September 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (9)
Real-life durability and risk factors for biologic discontinuation in pediatric inflammatory bowel disease: results from the SIGENP IBD registry
Background and aims: This study aims to evaluate the real-life durability of biologic therapies and to identify factors associated with biologic persistence in pediatric inflammatory bowel disease (IBD). Methods: We analyzed data from the IBD-registry of the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (SIGENP) of patients initiating biologics between 2009 and 2022 and ≥1-year follow-up. Results: A total of 1184 patients (747 with Crohn’s disease [CD], 437 with ulcerative colitis or IBD unclassified [UC/IBD-U]) were included, accounting for 1709 treatment courses. The median follow-up was 43 months (interquartile range 28-64). Overall, 33% received a second-line biologic, 9% third-line, and 2% fourth-line. First-line biologic durability was significantly lower in UC/IBD-U vs CD, with inferior persistence at 1, 2, and 3 years (61%, 51%, and 44% vs 88%, 75%, and 67%; hazard ratios [HR]: 1.5, 95% confidence interval [CI] 1.2-1.9, P = .002). In CD, infliximab had inferior durability then adalimumab (72%, 59%, and 50% vs 91%, 82%, and 77%; HR 2.0, 95% CI, 1.5-2.7, P < .0001). In both CD and UC/IBD-U, age <6 years was a risk factor for treatment discontinuation (HR 1.8, 95% CI, 1.2-2.7, P < .01) while therapeutic drug monitoring (TDM) emerged as protective (HR 0.5, 95% CI, 0.4-0.7, P < .0001). Combination with an immunomodulator had no significant impact on durability (HR 0.9, 95% CI, 0.8-1.2, P = .54). Conclusions: Biologic persistence varied by disease type and biologic agent. TDM was associated with longer treatment durability, while combination therapy had a limited effect. Further prospective studies are needed to refine biologics optimization strategies in pediatric IBD.